chr15-48596324-C-T
Variant summary
Our verdict is Pathogenic. Variant got 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000138.5(FBN1):c.497G>A(p.Cys166Tyr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 11/18 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. C166F) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000138.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 19 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FBN1 | NM_000138.5 | c.497G>A | p.Cys166Tyr | missense_variant | 6/66 | ENST00000316623.10 | NP_000129.3 | |
FBN1 | NM_001406716.1 | c.497G>A | p.Cys166Tyr | missense_variant | 5/65 | NP_001393645.1 | ||
FBN1 | NM_001406717.1 | c.497G>A | p.Cys166Tyr | missense_variant | 6/9 | NP_001393646.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FBN1 | ENST00000316623.10 | c.497G>A | p.Cys166Tyr | missense_variant | 6/66 | 1 | NM_000138.5 | ENSP00000325527.5 | ||
FBN1 | ENST00000559133.6 | n.497G>A | non_coding_transcript_exon_variant | 6/67 | 1 | ENSP00000453958.2 | ||||
FBN1 | ENST00000537463.6 | n.497G>A | non_coding_transcript_exon_variant | 6/31 | 5 | ENSP00000440294.2 | ||||
FBN1 | ENST00000674301.2 | n.497G>A | non_coding_transcript_exon_variant | 6/68 | ENSP00000501333.2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Marfan syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Juno Genomics, Hangzhou Juno Genomics, Inc | - | PM2_Supporting+PP3_Strong+PP2+PS4_Supporting+PP4 - |
Marfan Syndrome/Loeys-Dietz Syndrome/Familial Thoracic Aortic Aneurysms and Dissections Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 20, 2021 | Variant summary: FBN1 c.497G>A (p.Cys166Tyr) results in a non-conservative amino acid change located in the EGF-like domain (IPR000742) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. "The sulfhydryl group of cysteine is unique in its ability to participate in disulfide covalent cross-linkage. In fact, two-thirds of fibrillin cysteine residues exist in the half-cystinyl form, suggesting their participation in intramolecular disulfide linkage (Dietz_1992)". Therefore, the substitution of a cysteine may disrupt the structure of the FBN1 protein, affecting its function. The variant was absent in 251386 control chromosomes, however the available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.497G>A has been reported in the literature in an individual affected with Marfan Syndrome (example: Li_2019). Other variants at Cys166 have been reported in HGMD in association with Marfan Syndrome (C166R, C166F, C166S). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No ClinVar submitters have assessed this variant since 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Marfan syndrome;C4707243:Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 22, 2021 | This sequence change replaces cysteine with tyrosine at codon 166 of the FBN1 protein (p.Cys166Tyr). The cysteine residue is highly conserved and there is a large physicochemical difference between cysteine and tyrosine. This variant is not present in population databases (ExAC no frequency). This missense change has been observed in individual(s) with clinical features of Marfan syndrome (PMID: 31098894). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FBN1 protein function. This variant affects a cysteine residue in the EGF-like, TGFBP or hybrid motif domains of FBN1. Cysteine residues are believed to be involved in intramolecular disulfide bridges and have been shown to be important for FBN1 protein structure (PMID: 16905551, 19349279). In addition, missense substitutions affecting cysteine residues within these domains are significantly overrepresented among patients with Marfan syndrome (PMID: 16571647, 17701892). This variant disrupts the p.Cys166 amino acid residue in FBN1. Other variant(s) that disrupt this residue have been observed in individuals with FBN1-related conditions (PMID: 7611299, 14695540), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.